Charu Aggarwal

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-207
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-6318
Fax: 215-349-5326
Education:
MD
Lady Hardinge Medical College, New Delhi, India, 2003.
MPH (Health Care Organization and Policy)
University of Alabama at Birmingham, 2005.
Permanent link
 

Description of Itmat Expertise

Thoracic Oncology
Immunotherapy

Selected Publications

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans TL, Langer CJ: Determinants of Survival in Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapies. Clinical Lung Cancer July 2013.

Aggarwal, C: Nab-paclitaxel is a valuable NSCLC therapy option. Community Oncology 10(6), Jun 2013.

Aggarwal C, Dahlberg SE, Hanna N, Kolesar J, Hirsch FR, Ramalingam SS and Schiller JH : Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, IMC-A12, or both for advanced non-small cell lung cancer patients. Journal of Clinical Oncology 31s(abstr 8106), Jun 2013.

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans TL, Langer CJ: Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist? Lung Cancer June 2013.

Lustgarten DS, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer CJ, Inghilleri S, Stella G, Albelda SM : Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma Journal of Thoracic Oncology Volume 8 (4): 469–477, April 2013.

Aggarwal, C and Langer, CJ: Recent advances in the management of advanced Non Small Cell Lung Cancer. Community Oncology 10(4), Apr 2013.

Aggarwal C, Meropol N J, Punt C J, Iannotti N, Saidman B H, Sabbath K D, Gabrail N Y, Picus J, Morse M A, Mitchell E, Miller M C, Cohen S J: Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Annals of Oncology 24(2): 420-8, February 2013.

Aggarwal C, Ranganathan A, Lustgarten DS et al: Circulating Tumor Cells In Patients With Small Cell Lung Cancer: A Marker Of Disease Burden, Therapeutic Response, And Predictor Of Disease Relapse. Journal of Thoracic Oncology Sep 2012.

Brady A, McNeill JD, Judy B, Evans T, Cohen RB, Langer C, Vachani A AND Aggarwal C: Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer patients treated with first-line chemotherapy. Journal of Clinical Oncology Supplement Jun 2012.

Ranganathan A, Schwed-Lustgarten D, Aggarwal C et al: Circulating tumor cells in patients with small cell lung cancer: a marker of disease burden, therapeutic response, and predictor of disease relapse Journal of Clinical Oncology Supplement Jun 2012.

back to top
Last updated: 10/30/2017
The Trustees of the University of Pennsylvania